Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Research symbols : NTRA save search
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: 1.38%
H: 3.26%
C: 2.49%
milestone
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: 2.12%
H: 4.35%
C: 2.25%
bladder positive cancer trial
New Study Validates Signatera™ in Endometrial Cancer
Published: 2024-02-05 (Crawled : 13:30) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -0.89%
H: 2.74%
C: 2.52%
cancer study
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
Published: 2024-01-30 (Crawled : 13:30) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -1.07%
H: 1.73%
C: 0.46%
lung cancer publication risk
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
Published: 2023-12-21 (Crawled : 15:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: 1.62%
H: 5.36%
C: 3.57%
unique study benefits
In Vitro Diagnostics Market to Reach $138.4 Billion, Globally, by 2032 at 4.1% CAGR: Allied Market Research
Published: 2023-10-23 (Crawled : 14:00) - prnewswire.com
NVTA | News | $0.019 0.0% 22M
|
Health Services
|
| O: -7.0%
H: 0.0%
C: -3.35%
A | $137.49 -1.23% -0.36% 1.6M
|
Health Technology
|
| O: -1.03%
H: 1.67%
C: 1.15%
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -0.98%
H: 2.06%
C: -0.69%
ILMN | $122.74 -1.38% -1.4% 1.2M
|
Health Technology
|
| O: -0.87%
H: 1.73%
C: 0.73%
EXAS | $63.24 -0.46% -0.46% 1.2M
|
Health Technology
|
| O: -0.68%
H: 1.76%
C: 0.36%
reach research diagnostics market in vitro
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
Published: 2023-10-04 (Crawled : 15:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: 0.68%
H: 0.24%
C: -2.46%
lung cancer publication risk
Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer
Published: 2023-07-28 (Crawled : 15:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: 1.61%
H: 0.92%
C: -0.37%
cancer trial
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
Published: 2023-05-08 (Crawled : 14:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -0.07%
H: 0.37%
C: -1.78%
breast cancer publication trial
Genetic Testing Market to Reach $28.24 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report by Meticulous Research®
Published: 2023-03-20 (Crawled : 15:20) - prnewswire.com
TMO | News | $577.39 0.49% 0.0% 2M
|
Health Technology
|
| O: -0.11%
H: 1.48%
C: 0.7%
PKI | $115.24 0.0% 1.6M
|
Health Technology
|
| O: -2.64%
H: 2.21%
C: 1.27%
LH 4 | $207.94 -0.01% 0.0% 790K
|
Health Services
|
| O: 0.35%
H: 1.63%
C: 1.55%
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -0.23%
H: 1.0%
C: -0.42%
MYGN | $18.61 0.05% 0.05% 480K
|
Health Technology
|
| O: 0.74%
H: 2.75%
C: 2.15%
ILMN | $122.74 -1.38% -1.4% 1.2M
|
Health Technology
|
| O: -0.4%
H: 0.07%
C: -1.73%
FLGT | $20.75 0.53% 0.53% 150K
|
Health Services
|
| O: 0.81%
H: 2.64%
C: -0.23%
CNTG | $0.475 -1.04% -1.05% 19K
|
Commercial Services
|
| O: 5.53%
H: 0.0%
C: -9.28%
research report genetic trends market
Natera Announces Commercial Payor Coverage for Signatera™
Published: 2023-03-02 (Crawled : 14:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -2.21%
H: 7.27%
C: 6.39%
commercial
Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera’s Ability to Predict Chemotherapy Benefit in Colorectal Cancer
Published: 2023-01-17 (Crawled : 14:20) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -1.05%
H: 1.4%
C: -3.33%
cancer publication study
Natera Supports Updated ISHLT Guidelines for the Care of Heart Transplant Patients
Published: 2022-12-22 (Crawled : 13:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -1.73%
H: 4.73%
C: 4.68%
guidelines care heart
Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers
Published: 2022-12-09 (Crawled : 17:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -0.34%
H: 1.76%
C: -1.27%
publication study
New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients
Published: 2022-11-21 (Crawled : 15:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -0.79%
H: 2.91%
C: -0.14%
melanoma immunotherapy technology response study
New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer
Published: 2022-10-06 (Crawled : 13:20) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: 0.45%
H: 1.75%
C: 0.38%
test cancer publication ovarian cancer
Natera Announces 2025 ESG Goals with Publication of 2021 Report
Published: 2022-09-29 (Crawled : 14:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -1.32%
H: 0.61%
C: -2.13%
report esg publication
Global Minimal Residual Disease (MRD) Testing Market to Reach $2.61 billion by 2027, Suggest a Latest BIS Research Study
Published: 2022-06-10 (Crawled : 13:00) - prnewswire.com
DGX | News | $137.55 0.62% 0.0% 1.6M
|
Health Services
|
| O: -1.79%
H: 0.0%
C: 0.0%
LH 4 | $207.94 -0.01% 0.0% 790K
|
Health Services
|
| O: -4.59%
H: 0.0%
C: 0.0%
BIO | $278.21 -2.48% 0.0% 210K
|
Health Technology
|
| O: -4.44%
H: 0.0%
C: 0.0%
OPK | $1.225 -2.0% -2.04% 6.1M
|
Health Technology
|
| O: -4.2%
H: 0.0%
C: 0.0%
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -7.01%
H: 0.0%
C: 0.0%
ICLR | News | $308.79 0.76% 0.76% 960K
|
Health Technology
|
| O: -3.06%
H: 0.0%
C: 0.0%
ADPT | $2.595 0.58% 0.39% 2M
|
Commercial Services
|
| O: -6.61%
H: 0.0%
C: 0.0%
research disease market test
Natera Announces Results of Large, Multi-Center Clinical Experience Study Showing Excellent Positive Predictive Value of the Prospera™ Kidney Test
Published: 2022-02-17 (Crawled : 14:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -1.52%
H: 0.84%
C: -6.69%
kidney cel test positive results
Natera Validates Prospera™ With Quantification in Multi-Site, Prospective Trifecta Study
Published: 2021-11-03 (Crawled : 13:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K
|
Health Services
|
| O: -4.41%
H: 0.87%
C: -1.24%
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.